tiprankstipranks
Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
US Market
UNCY
Unicycive Therapeutics
RESEARCH TOOLSreports

Unicycive Therapeutics (UNCY) Stock Forecast & Price Target

841 Followers
See the Price Targets and Ratings of:

UNCY Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Unicycive
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

UNCY Stock 12 Month Forecast

Average Price Target

$49.83
▲(651.58% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Unicycive Therapeutics in the last 3 months. The average price target is $49.83 with a high forecast of $90.00 and a low forecast of $15.00. The average price target represents a 651.58% change from the last price of $6.63.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","25":"$25","47":"$47","69":"$69","91":"$91"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$49.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,25,47,69,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.12,13.495384615384616,19.87076923076923,26.246153846153845,32.62153846153846,38.996923076923075,45.372307692307686,51.7476923076923,58.123076923076916,64.49846153846154,70.87384615384615,77.24923076923076,83.62461538461538,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.12,10.405384615384616,13.69076923076923,16.976153846153846,20.26153846153846,23.54692307692308,26.832307692307694,30.11769230769231,33.403076923076924,36.68846153846154,39.973846153846154,43.25923076923077,46.54461538461538,{"y":49.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.12,7.726153846153847,8.332307692307692,8.938461538461539,9.544615384615385,10.150769230769232,10.756923076923076,11.363076923076923,11.96923076923077,12.575384615384616,13.181538461538462,13.787692307692307,14.393846153846155,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.46,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.77,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.99,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.12,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$90.00Average Price Target$49.83Lowest Price Target$15.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Benchmark Co. Analyst forecast on UNCY
Bruce Jackson
Benchmark Co.
Benchmark Co.
$21→$15
Buy
126.24%
Upside
Reiterated
04/06/26
Unicycive Therapeutics price target lowered to $15 from $21 at BenchmarkUnicycive Therapeutics price target lowered to $15 from $21 at Benchmark
Guggenheim Analyst forecast on UNCY
Vamil Divan
Guggenheim
Guggenheim
$46→$40
Buy
503.32%
Upside
Reiterated
04/01/26
Unicycive Therapeutics price target lowered to $40 from $46 at GuggenheimUnicycive Therapeutics price target lowered to $40 from $46 at Guggenheim
H.C. Wainwright Analyst forecast on UNCY
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
$22
Buy
231.83%
Upside
Reiterated
03/31/26
H.C. Wainwright Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY)
Noble Financial Analyst forecast on UNCY
Robert LeBoyer
Noble Financial
Noble Financial
$60
Buy
804.98%
Upside
Reiterated
03/31/26
Analysts Are Bullish on These Healthcare Stocks: Unicycive Therapeutics (UNCY), Biomea Fusion (BMEA)
Piper Sandler Analyst forecast on UNCY
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$90
Buy
1257.47%
Upside
Reiterated
02/27/26
Piper Sandler Remains a Buy on Unicycive Therapeutics (UNCY)
Westpark Capital Analyst forecast on UNCY
Unknown Analyst
Westpark Capital
Not Ranked
Westpark Capital
$72
Buy
985.97%
Upside
Initiated
02/19/26
Unicycive Therapeutics (UNCY) Gets a Buy from Westpark Capital
Maxim Group Analyst forecast on UNCY
Jason McCarthy
Maxim Group
Maxim Group
$30
Buy
352.49%
Upside
Reiterated
12/29/25
De-Risked NDA Resubmission and TDAPA Tailwinds Support Buy Rating on Unicycive and OLC Commercial Upside
Lucid Capital Analyst forecast on UNCY
Elemer Piros
Lucid Capital
Lucid Capital
$120
Buy
1709.95%
Upside
Initiated
06/04/25
Unicycive Therapeutics (UNCY) Receives a Buy from H.C. Wainwright
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Benchmark Co. Analyst forecast on UNCY
Bruce Jackson
Benchmark Co.
Benchmark Co.
$21→$15
Buy
126.24%
Upside
Reiterated
04/06/26
Unicycive Therapeutics price target lowered to $15 from $21 at BenchmarkUnicycive Therapeutics price target lowered to $15 from $21 at Benchmark
Guggenheim Analyst forecast on UNCY
Vamil Divan
Guggenheim
Guggenheim
$46→$40
Buy
503.32%
Upside
Reiterated
04/01/26
Unicycive Therapeutics price target lowered to $40 from $46 at GuggenheimUnicycive Therapeutics price target lowered to $40 from $46 at Guggenheim
H.C. Wainwright Analyst forecast on UNCY
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
$22
Buy
231.83%
Upside
Reiterated
03/31/26
H.C. Wainwright Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY)
Noble Financial Analyst forecast on UNCY
Robert LeBoyer
Noble Financial
Noble Financial
$60
Buy
804.98%
Upside
Reiterated
03/31/26
Analysts Are Bullish on These Healthcare Stocks: Unicycive Therapeutics (UNCY), Biomea Fusion (BMEA)
Piper Sandler Analyst forecast on UNCY
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$90
Buy
1257.47%
Upside
Reiterated
02/27/26
Piper Sandler Remains a Buy on Unicycive Therapeutics (UNCY)
Westpark Capital Analyst forecast on UNCY
Unknown Analyst
Westpark Capital
Not Ranked
Westpark Capital
$72
Buy
985.97%
Upside
Initiated
02/19/26
Unicycive Therapeutics (UNCY) Gets a Buy from Westpark Capital
Maxim Group Analyst forecast on UNCY
Jason McCarthy
Maxim Group
Maxim Group
$30
Buy
352.49%
Upside
Reiterated
12/29/25
De-Risked NDA Resubmission and TDAPA Tailwinds Support Buy Rating on Unicycive and OLC Commercial Upside
Lucid Capital Analyst forecast on UNCY
Elemer Piros
Lucid Capital
Lucid Capital
$120
Buy
1709.95%
Upside
Initiated
06/04/25
Unicycive Therapeutics (UNCY) Receives a Buy from H.C. Wainwright
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Unicycive Therapeutics

3 Months
xxx
Success Rate
5/11 ratings generated profit
45%
Average Return
+3.94%
reiterated a xxx
 rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +3.94% per trade.
1 Year
Jason McCarthyMaxim Group
Success Rate
10/11 ratings generated profit
91%
Average Return
+16.45%
reiterated a buy rating 4 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +16.45% per trade.
2 Years
xxx
Success Rate
10/11 ratings generated profit
91%
Average Return
+30.75%
reiterated a xxx
 rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +30.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

UNCY Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
10
8
7
8
7
Buy
0
0
0
0
0
Hold
1
22
23
24
9
Sell
0
1
1
3
2
Strong Sell
0
0
0
0
0
total
11
31
31
35
18
In the current month, UNCY has received 7 Buy Ratings, 9 Hold Ratings, and 2 Sell Ratings. UNCY average Analyst price target in the past 3 months is 49.83.
Each month's total comprises the sum of three months' worth of ratings.

UNCY Financial Forecast

UNCY Earnings Forecast

The previous quarter’s earnings for UNCY were -$0.32.
The previous quarter’s earnings for UNCY were -$0.32.

UNCY Sales Forecast

The previous quarter’s earnings for UNCY were $0.00.
The previous quarter’s earnings for UNCY were $0.00.

UNCY Stock Forecast FAQ

What is UNCY’s average 12-month price target, according to analysts?
Based on analyst ratings, Unicycive Therapeutics’s 12-month average price target is 49.83.
    What is UNCY’s upside potential, based on the analysts’ average price target?
    Unicycive Therapeutics has 651.58% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is UNCY a Buy, Sell or Hold?
          Unicycive Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Unicycive Therapeutics’s price target?
            The average price target for Unicycive Therapeutics is 49.83. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $90.00 ,the lowest forecast is $15.00. The average price target represents 651.58% Increase from the current price of $6.63.
              What do analysts say about Unicycive Therapeutics?
              Unicycive Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of UNCY?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.